ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression
about
The epigenetic landscape of acute myeloid leukemiaBAP1 is phosphorylated at serine 592 in S-phase following DNA damageThe Functional Role of PRC2 in Early T-cell Precursor Acute Lymphoblastic Leukemia (ETP-ALL) - Mechanisms and OpportunitiesEpigenetic regulators and their impact on therapy in acute myeloid leukemiaEvolving Therapeutic Strategies for the Classic Philadelphia-Negative Myeloproliferative NeoplasmsCytogenetic and molecular abnormalities in chronic myelomonocytic leukemiaRevealing the Complexity of Breast Cancer by Next Generation SequencingEZH2 in normal hematopoiesis and hematological malignanciesGenetics of myeloproliferative neoplasmsMechanisms of epigenetic regulation of leukemia onset and progressionThe genetics of uveal melanoma: current insightsEpigenetics in Cancer: A Hematological PerspectiveHeterozygous and homozygous JAK2(V617F) states modeled by induced pluripotent stem cells from myeloproliferative neoplasm patientsAdditional sex combs-like family genes are required for normal cardiovascular developmentMyelodysplastic syndromes are induced by histone methylation–altering ASXL1 mutationsEpigenetic States of nephron progenitors and epithelial differentiation.Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia.Minireview: transgenerational epigenetic inheritance: focus on endocrine disrupting compoundsDeletion of Asxl1 results in myelodysplasia and severe developmental defects in vivoCombining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes.CAPRI: efficient inference of cancer progression models from cross-sectional data.Epigenetics in normal and malignant hematopoiesis: An overview and update 2017.A molecular revolution in uveal melanoma: implications for patient care and targeted therapyASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemia.Prognostic value of isocitrate dehydrogenase mutations in myelodysplastic syndromes: a retrospective cohort study and meta-analysis.The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemiaLoss of Asxl2 leads to myeloid malignancies in micemiR-155 activates cytokine gene expression in Th17 cells by regulating the DNA-binding protein Jarid2 to relieve polycomb-mediated repression.The distinct biological implications of Asxl1 mutation and its roles in leukemogenesis revealed by a knock-in mouse modelThe changing mutational landscape of acute myeloid leukemia and myelodysplastic syndrome.Histone methyltransferase MMSET/NSD2 alters EZH2 binding and reprograms the myeloma epigenome through global and focal changes in H3K36 and H3K27 methylationEZH2 in normal and malignant hematopoiesis.TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patientsFunctional proteomics of the epigenetic regulators ASXL1, ASXL2 and ASXL3: a convergence of proteomics and epigenetics for translational medicine.The BAP1/ASXL2 Histone H2A Deubiquitinase Complex Regulates Cell Proliferation and Is Disrupted in Cancer.High-throughput chromatin immunoprecipitation for genome-wide mapping of in vivo protein-DNA interactions and epigenomic states.Concise review: preleukemic stem cells: molecular biology and clinical implications of the precursors to leukemia stem cellsMutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia.Additional sex combs-like 2 is required for polycomb repressive complex 2 binding at select targetsThe histone deacetylase inhibitor SAHA sensitizes acute myeloid leukemia cells to a combination of nucleoside analogs and the DNA-alkylating agent busulfan.
P2860
Q21284742-FE25CAB2-6E22-4308-BB89-A1ACFBD96D16Q24339530-8AE6698C-CC87-4900-9A2A-164B360738C3Q26744506-6B59BEC1-B83C-4B1E-B5A1-6B0E3C81F566Q26765402-5F9DA916-DE17-4746-9EC7-C89F2C8D4EC6Q26766319-61A204F2-4574-4D24-9317-85AF0C925ED8Q26768600-B4C2E5B2-CACF-4ABB-8811-303FE6FEC5BCQ26777395-B6084F6C-A258-4D52-A19C-A0F5F112BFD1Q26779821-58D59873-F593-43A0-BE10-339934810ADDQ26823651-C10762FF-74F0-409C-8466-CADF1DD548A1Q26861785-2E766AFE-9926-479D-AA0A-5CDD98987791Q28073150-EB709809-77D3-4117-8E67-C6A76E95BAA4Q28077082-F77A52BD-9488-4BA2-8F92-5015B4AE72CFQ28533511-FA1908F3-99BF-4008-8EB0-F6586CFE54F6Q28585968-A2D18947-99EA-4C7B-B358-FC62FC76F518Q28590040-C712B147-CCF9-4272-B175-567B0BADA648Q30301009-A443B134-E161-4743-96F4-239904F9DCF0Q30313615-FC6B9294-56ED-438E-AA1C-78770F2BD8E3Q30371599-42B02513-DAED-4506-AA6E-021E20D75BBAQ30413034-B667855D-FAC8-4875-BBDB-BC9626787D11Q30883788-923219C2-C49C-4BB3-B2F2-7905F02733F6Q30951310-7D9389EF-4D30-4D70-B419-38207776FFAEQ33607609-C88061F1-F6CB-4914-8509-E7A0E6A82608Q33717375-31EAC59B-ECC4-43A6-BB1E-33D29F2FA2BCQ33753763-9585AA49-7AC0-4283-AACC-486CED1E4CADQ33769072-0B430336-E9D9-443A-B675-51E48F621376Q33796552-67662F16-C4F3-4D30-833C-95B963917022Q33802946-C5442499-AEE3-4B03-ADC0-874AF87C8300Q33882867-4AA229E9-CF30-4AE3-BB91-5F07CF7E226FQ33892323-816AC715-F203-4230-A0EF-E3FE202ACD0CQ34010735-8CFA46F3-60CA-4014-A79D-D4A12A3F593DQ34133622-72164AE6-70F3-4290-9302-51E45F172725Q34375614-0EA527B1-DE07-4614-9060-C3597721BC59Q34398397-72A4B961-E7F1-4915-806B-0C8B0F43AE1EQ34469971-AD7C7F58-28DB-47D5-8110-AFEEC4759474Q34496129-743F3AB3-F557-40A0-ADDA-44BBEFB27944Q34594554-81B684B4-D972-4B47-BAAB-813BBA47EF28Q34647637-027BF6B9-399B-401A-A7FA-1057FC5DB641Q34651312-7C271A3C-ED83-434D-AF3A-01A82F354805Q34989584-1AA0B6D2-5400-467A-9285-3756007218C2Q35060679-36FE6174-4DF8-484B-815F-59FE41617237
P2860
ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression
description
2012 nî lūn-bûn
@nan
2012 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
ASXL1 mutations promote myeloi ...... PRC2-mediated gene repression
@ast
ASXL1 mutations promote myeloi ...... PRC2-mediated gene repression
@en
ASXL1 mutations promote myeloi ...... PRC2-mediated gene repression
@en-gb
ASXL1 mutations promote myeloi ...... PRC2-mediated gene repression
@nl
type
label
ASXL1 mutations promote myeloi ...... PRC2-mediated gene repression
@ast
ASXL1 mutations promote myeloi ...... PRC2-mediated gene repression
@en
ASXL1 mutations promote myeloi ...... PRC2-mediated gene repression
@en-gb
ASXL1 mutations promote myeloi ...... PRC2-mediated gene repression
@nl
prefLabel
ASXL1 mutations promote myeloi ...... PRC2-mediated gene repression
@ast
ASXL1 mutations promote myeloi ...... PRC2-mediated gene repression
@en
ASXL1 mutations promote myeloi ...... PRC2-mediated gene repression
@en-gb
ASXL1 mutations promote myeloi ...... PRC2-mediated gene repression
@nl
P2093
P2860
P50
P3181
P1433
P1476
ASXL1 mutations promote myeloi ...... PRC2-mediated gene repression
@en
P2093
Alan H Shih
Ari Melnick
Bradley E Bernstein
Christopher Y Park
Iannis Aifantis
Jacob D Jaffe
Jay P Patel
Jordan E Taylor
Lindsay M LaFave
P2860
P304
P3181
P356
10.1016/J.CCR.2012.06.032
P407
P5008
P577
2012-08-14T00:00:00Z